FDG-PET-CT for staging of high-risk breast cancer patients reduces the number of further examinations: A pilot study

Acta Oncologica

Volumn 49, Issue 2, 2010, Pages 185-191

  Jager, Jos ^a,b   Keymeulen, Kristien ^b   Beets Tan, Regina G H ^b   Hupperets, Pierre ^b   Van Kroonenburgh, Marinus ^b   Houben, Ruud ^a   De Ruysscher, Dirk ^a,b   Lambin, Philippe ^a,b   Boersma, Liesbeth J ^a,b  

^a MAASTRO CLINIC   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; BONE SCINTISCANNING; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LYMPH NODE METASTASIS; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

ADULT; BREAST NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM STAGING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 76649113414     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903440262     Document Type: Article

References (20)

1. Pestalozzi B, Castiglione M, on behalf of the ESMO guidelines working group. Primary breast cancer:ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):ii7-ii10.
2. Hoeven van der JJM, Krak NC, Hoekstra OS, Comans EF, Boom RP, van Geldere D, et al. 18F-2-Fluoro-2-Deoxy-D-Glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 2004;22:1253-9.
3. Oost van FJ, Hoeven van der JJM, Hoekstra OS, Voogd AC, Coebergh JW, van de Poll-Franse LV. Staging in patients with locoregionally recurrent breast cancer:Current practice and prospects for positron emission tomography. Eur J Cancer 2004;40:1545-53.
4. Port ES, Yeung H, Gonen M, Liberman L, Caravelli J, Borgen P, et al. FDG-PET scanning affects surgical management in selected patients with high-risk operable breast carcinoma. Ann Surg Oncol 2006;13:677-84.
5. Mahner S, Schirmacher S, Brenner W, Jenicke L, Habermann CR, Avril N, et al. Comparison between FDG-PET, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008;19:1249-54.
6. 18Flurorodeoxyglucose positron emission tomography to detect mediastinal mammary or internal mammary metastases in breast cancer. J Clin Oncol 2001;19:3516-23.
7. 18F-FDG-PET in the local-regional evaluation of women with breast cancer. Breast Cancer Res Treat 2002;75:135-46.
8. 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 2003;44:24-9.
9. Groheux D, Moretti J-L, Baillet G, Espie M, Giacchetti S, Hindie E, et al. Effect of 18F-FDG PET-CT imaging in patients with clinical stage II and III breast cancer. Int J Radiat Oncol Biol Phys 2008;71:1-10.
10. Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G, et al. Preoperative staging of large primary breast cancer with [18F]Fluorodeoxyglucose positron emission tomography-computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:4746-51.
11. Dose J, Bleckmann C, Bachmann S, Velasco M, Muñoz M, Santamaría G, et al. Comparison of FDG-PET and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Comm 2002;23:857-64.
12. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast recurrence and metastases. Breast Cancer Res Treat 2005;90:105-12.
13. Eubank WB, Mankoff D, Bhattacharya M, Gralow J, Linden H, Ellis G, et al. Impact of FDG-PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. Am J Rontgenol 2004;183:479-86.
14. Gerber B, Seitz E, Muller H, Krause A, Reimer T, Kundt G, et al. Peri-operative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread. Breast Cancer Res Treat 2003;82:29-37.
15. Cermik TF, Mavi A, Basu S, Alavi A. Impact of FDG-PET on pre-operative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging 2008;35:475-83.
16. Bellon JR, Livingston RB, Eubank WB, Gralow JR, Ellis GK, Dunnwald LK, et al. Evaluation of the internal mammary nodes by FDG-PET in locally advanced breast cancer. Am J Clin Oncol 2004;27:407-10.
17. Shie P, Cardareli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis:Comparison of FDG-PET and bone scintig-raphy in the detection of bone metastases in patients with breast cancer. Clin Nucl Med 2008;33:97-101.
18. Dietrich CF, Kratzer W, Strobe D, Danse E, Fessl R, Bunk A, et al. Assessment of metastatic liver disease in patients with extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006;12:1699-705.
19. Klaeser B, Wiederkehr O, Koeberle D, Mueller A, Bubeck B, Thuerlimann B. Therapeutic impact of FDG-PET in the pre-and post-operative staging of patients with clinically intermediate or high-risk breast cancer. Ann Oncol 2007;18:1329-34.
20. Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DHS. FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors. Comparison with longterm clinical outcome. J Nucl Med 2005;46:1455-9.